Previous close | 1.0000 |
Open | 1.0000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 60.00 |
Expiry date | 2024-05-17 |
Day's range | 1.0000 - 1.0000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metast
Merus N.V. ( NASDAQ:MRUS ) shareholders are probably feeling a little disappointed, since its shares fell 7.9% to...
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...